AtonRa Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $659K | Sell |
5,002
-560
| -10% | -$73.8K | 1.31% | 17 |
|
|
2023
Q3 | $626K | Sell |
5,562
-1,293
| -19% | -$145K | 1.31% | 14 |
|
|
2023
Q2 | $646K | Sell |
6,855
-456
| -6% | -$43K | 1% | 28 |
|
|
2023
Q1 | $740K | Sell |
7,311
-688
| -9% | -$69.6K | 1.08% | 28 |
|
|
2022
Q4 | $955K | Sell |
7,999
-3,187
| -28% | -$381K | 1.22% | 27 |
|
|
2022
Q3 | $1.19M | Sell |
11,186
-255
| -2% | -$27.1K | 1.17% | 26 |
|
|
2022
Q2 | $1.12M | Sell |
11,441
-2,148
| -16% | -$209K | 1.03% | 35 |
|
|
2022
Q1 | $1.27M | Buy |
13,589
+680
| +5% | +$63.8K | 0.69% | 66 |
|
|
2021
Q4 | $1.1M | Buy |
12,909
+1,091
| +9% | +$92.9K | 0.38% | 87 |
|
|
2021
Q3 | $1.13M | Buy |
11,818
+915
| +8% | +$87.7K | 0.38% | 93 |
|
|
2021
Q2 | $1.06M | Sell |
10,903
-17,510
| -62% | -$1.7M | 0.39% | 90 |
|
|
2021
Q1 | $2.76M | Buy |
28,413
+2,986
| +12% | +$290K | 1.23% | 30 |
|
|
2020
Q4 | $2.44M | Buy |
+25,427
| New | +$2.44M | 1.2% | 35 |
|